Save Ceftolozane/Tazobactam for Resistant E. coli or Pseudomonas

Please see the FDA safety warning (May 2015) concerning dose confusion/medication errors associated with Zerbaxa

Reps will be promoting a new IV anti-infective, ceftolozane/tazobactam (Zerbaxa).

It's approved for complicated UTIs (cUTIs) and intra-abdominal infections (cIAIs) in adults. And higher doses are also being studied for ventilator-associated pneumonia.

Ceftolozane/tazobactam primarily covers gram-negative bacteria...including Pseudomonas and ESBL-producing Enterobacteriaceae.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote